Download PDF
Semin intervent Radiol 2023; 40(06): 524-535
DOI: 10.1055/s-0043-1777846
Review Article

Hepatocellular Carcinoma from a Hepatologist's Perspective

Giovanni A. Roldan
1   Department of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, Minnesota
,
Jacquelin Blomker
2   Department of Medicine, University of Minnesota, Minneapolis, Minnesota
,
Elizabeth S. Aby
1   Department of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, Minnesota
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, represents a growing health challenge worldwide. The incidence of HCC is rising, which, in turn, has led to a corresponding increase in the associated number of deaths. HCC will become the third leading cause of cancer-related deaths in the United States by 2030. HCC usually develops in the setting of chronic liver disease. Individuals at increased risk of HCC are recommended to undergo surveillance with ultrasound every 6 months along with serum α-fetoprotein testing. Computed tomography (CT) and magnetic resonance imaging (MRI) are considered alternatives based on specific patient factors. Lesions suspicious for HCC are recommended to undergo a diagnostic testing, which includes contrast-enhanced multiphase CT or MRI and liver biopsy when findings are indeterminate. The Barcelona Clinic Liver Cancer prognosis and treatment strategy is the most used assessment for patients with HCC ([Fig. 2]). Curative therapies include resection, liver transplantation, and ablation. Locoregional therapies, such as transarterial chemoembolization and radioembolization, can be used for patients with intermediate-stage HCC. For patients with advanced-stage HCC, systemic therapy is often used. This review aims to provide an overview of HCC from a hepatologist's perspective, including epidemiology, screening, surveillance, diagnosis, and management.

Keywords

interventional radiology - hepatology - hepatocellular carcinoma - hepatoma - epidemiology - screening - surveillance

Authors' Contributions

G.A.R., J.B., and E.S.A. contributed to the study concept and design. G.A.R., J.B., and E.S.A. drafted the manuscript. E.S.A. provided critical revisions.


Financial Support

None.




Publication History

Article published online:
24 January 2024

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedGoogle Scholar
  • 2 Ryerson AB, Eheman CR, Altekruse SF. et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016; 122 (09) 1312-1337
    CrossrefPubMedGoogle Scholar
  • 3 Arnold M, Abnet CC, Neale RE. et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020; 159 (01) 335-349.e15
    CrossrefPubMedGoogle Scholar
  • 4 Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74 (11) 2913-2921
    CrossrefPubMedGoogle Scholar
  • 5 Yang JD, Altekruse SF, Nguyen MH, Gores GJ, Roberts LR. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer 2017; 123 (01) 81-89
    CrossrefPubMedGoogle Scholar
  • 6 Makarova-Rusher OV, Altekruse SF, McNeel TS. et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016; 122 (11) 1757-1765
    CrossrefPubMedGoogle Scholar
  • 7 Welzel TM, Graubard BI, Quraishi S. et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013; 108 (08) 1314-1321
    CrossrefPubMedGoogle Scholar
  • 8 Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology 2019; 157 (01) 54-64
    CrossrefPubMedGoogle Scholar
  • 9 Llovet JM, Kelley RK, Villanueva A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7 (01) 6
    CrossrefPubMedGoogle Scholar
  • 10 Brown ZJ, Tsilimigras DI, Ruff SM. et al. Management of hepatocellular carcinoma: a review. JAMA Surg 2023; 158 (04) 410-420
    CrossrefPubMedGoogle Scholar
  • 11 Reddy KR, McLerran D, Marsh T. et al. Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study. Gastroenterology 2023; 165 (04) 1053-1063.e6
    CrossrefPubMedGoogle Scholar
  • 12 EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. Accessed November 5, 2023 at: https://www.journal-of-hepatology.eu/article/S0168-8278(18)30215-0/fulltext
    PubMed
  • 13 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021; 18 (04) 223-238
    CrossrefPubMedGoogle Scholar
  • 14 Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022; 400 (10360): 1345-1362
    CrossrefPubMedGoogle Scholar
  • 15 Wong GLH, Chan HLY, Mak CWH. et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58 (05) 1537-1547
    CrossrefPubMedGoogle Scholar
  • 16 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
    CrossrefPubMedGoogle Scholar
  • 17 Singal AG, Llovet JM, Yarchoan M. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023; 78 (06) 1922-1965
    CrossrefPubMedGoogle Scholar
  • 18 Omata M, Cheng AL, Kokudo N. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11 (04) 317-370
    CrossrefPubMedGoogle Scholar
  • 19 Hanna RF, Miloushev VZ, Tang A. et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 2016; 41 (01) 71-90
    CrossrefPubMedGoogle Scholar
  • 20 Chang TS, Wu YC, Tung SY. et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol 2015; 110 (06) 836-844 , quiz 845
    CrossrefPubMedGoogle Scholar
  • 21 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130 (07) 417-422
    CrossrefPubMedGoogle Scholar
  • 22 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11 (04) e1001624
    CrossrefPubMedGoogle Scholar
  • 23 Singal AG, Zhang E, Narasimman M. et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol 2022; 77 (01) 128-139
    CrossrefPubMedGoogle Scholar
  • 24 Stine JG, Wentworth BJ, Zimmet A. et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018; 48 (07) 696-703
    CrossrefPubMedGoogle Scholar
  • 25 Kanwal F, Kramer JR, Mapakshi S. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018; 155 (06) 1828-1837.e2
    CrossrefPubMedGoogle Scholar
  • 26 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10 (12) 1342-1359.e2
    CrossrefPubMedGoogle Scholar
  • 27 Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 2020; 158 (06) 1822-1830
    CrossrefPubMedGoogle Scholar
  • 28 Simmons O, Fetzer DT, Yokoo T. et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017; 45 (01) 169-177
    CrossrefPubMedGoogle Scholar
  • 29 Schoenberger H, Chong N, Fetzer DT. et al. Dynamic changes in ultrasound quality for hepatocellular carcinoma screening in patients with cirrhosis. Clin Gastroenterol Hepatol 2022; 20 (07) 1561-1569.e4
    CrossrefPubMedGoogle Scholar
  • 30 Tzartzeva K, Obi J, Rich NE. et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018; 154 (06) 1706-1718.e1
    CrossrefPubMedGoogle Scholar
  • 31 Rodgers SK, Fetzer DT, Gabriel H. et al. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019; 39 (03) 690-708
    CrossrefPubMedGoogle Scholar
  • 32 Atiq O, Tiro J, Yopp AC. et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 2017; 65 (04) 1196-1205
    CrossrefPubMedGoogle Scholar
  • 33 Kim SY, An J, Lim YS. et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol 2017; 3 (04) 456-463
    CrossrefPubMedGoogle Scholar
  • 34 Roberts LR, Sirlin CB, Zaiem F. et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018; 67 (01) 401-421
    CrossrefPubMedGoogle Scholar
  • 35 An JY, Peña MA, Cunha GM. et al. Abbreviated MRI for hepatocellular carcinoma screening and surveillance. Radiographics 2020; 40 (07) 1916-1931
    CrossrefPubMedGoogle Scholar
  • 36 Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol 2021; 75 (01) 108-119
    CrossrefPubMedGoogle Scholar
  • 37 Narasimman M, Hernaez R, Cerda V. et al. Financial burden of hepatocellular carcinoma screening in patients with cirrhosis. Clin Gastroenterol Hepatol 2023
    PubMedGoogle Scholar
  • 38 Petrasek J, Singal AG, Rich NE. Harms of hepatocellular carcinoma surveillance. Curr Hepatol Rep 2019; 18 (04) 383-389
    CrossrefPubMedGoogle Scholar
  • 39 Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program. Liver Transpl 2019; 25 (03) 369-379
    CrossrefPubMedGoogle Scholar
  • 40 Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era?. J Hepatol 2023; 78 (01) 207-216
    CrossrefPubMedGoogle Scholar
  • 41 Berhane S, Toyoda H, Tada T. et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016; 14 (06) 875-886.e6
    CrossrefPubMedGoogle Scholar
  • 42 Wang M, Devarajan K, Singal AG. et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prev Res (Phila) 2016; 9 (02) 172-179
    CrossrefPubMedGoogle Scholar
  • 43 Tayob N, Christie I, Richardson P. et al. Validation of the hepatocellular carcinoma early detection screening (HES) algorithm in a cohort of Veterans with cirrhosis. Clin Gastroenterol Hepatol 2019; 17 (09) 1886-1893.e5
    CrossrefPubMedGoogle Scholar
  • 44 Cunha GM, Sirlin CB, Fowler KJ. Imaging diagnosis of hepatocellular carcinoma: LI-RADS. Chin Clin Oncol 2021; 10 (01) 3 DOI: 10.21037/cco-20-107.
    CrossrefPubMedGoogle Scholar
  • 45 Zhang YD, Zhu FP, Xu X. et al. Classifying CT/MR findings in patients with suspicion of hepatocellular carcinoma: comparison of liver imaging reporting and data system and criteria-free Likert scale reporting models. J Magn Reson Imaging 2016; 43 (02) 373-383
    CrossrefPubMedGoogle Scholar
  • 46 van der Pol CB, Lim CS, Sirlin CB. et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy - a systematic review. Gastroenterology 2019; 156 (04) 976-986
    CrossrefPubMedGoogle Scholar
  • 47 Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: An update. World J Hepatol 2021; 13 (04) 393-410
    CrossrefPubMedGoogle Scholar
  • 48 International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49 (02) 658-664
    CrossrefPubMedGoogle Scholar
  • 49 Tremosini S, Forner A, Boix L. et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 2012; 61 (10) 1481-1487
    CrossrefPubMedGoogle Scholar
  • 50 Seif El Dahan K, Reczek A, Daher D. et al. Multidisciplinary care for patients with HCC: a systematic review and meta-analysis. Hepatol Commun 2023; 7 (05) e0143
    CrossrefPubMedGoogle Scholar
  • 51 Salgia R, Mendiratta V. The multidisciplinary management of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2021; 17 (06) 405-408
    CrossrefPubMedGoogle Scholar
  • 52 Kim KM, Shim SG, Sinn DH, Song JE, Kim BS, Kim HG. Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites?. Scand J Gastroenterol 2020; 55 (08) 951-957
    CrossrefPubMedGoogle Scholar
  • 53 Johnson PJ, Berhane S, Kagebayashi C. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33 (06) 550-558
    CrossrefPubMedGoogle Scholar
  • 54 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep Innov Hepatol 2021; 3 (05) 100347
    CrossrefPubMedGoogle Scholar
  • 55 Pinato DJ, Sharma R, Allara E. et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66 (02) 338-346
    CrossrefPubMedGoogle Scholar
  • 56 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76 (03) 681-693
    CrossrefPubMedGoogle Scholar
  • 57 Borzio M, Dionigi E, Rossini A. et al. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study. Hepatology 2018; 67 (06) 2215-2225
    CrossrefPubMedGoogle Scholar
  • 58 Okuda K, Ohtsuki T, Obata H. et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56 (04) 918-928
    CrossrefPubMedGoogle Scholar
  • 59 A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators - PubMed. Accessed November 5, 2023 at: https://pubmed.ncbi.nlm.nih.gov/9731568/
    PubMed
  • 60 Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol 2018; 37 (06) 481-491
    CrossrefPubMedGoogle Scholar
  • 61 Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014; 34 (04) 444-455
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?. Cancer 2000; 88 (03) 538-543
    CrossrefPubMedGoogle Scholar
  • 63 Llovet JM, Bruix J, Fuster J. et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998; 27 (06) 1572-1577
    CrossrefPubMedGoogle Scholar
  • 64 Vauthey JN, Dixon E, Abdalla EK. et al; American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, Society for Surgery of the Alimentary Tract. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12 (05) 289-299
    CrossrefPubMedGoogle Scholar
  • 65 Mazzaferro V, Citterio D, Bhoori S. et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020; 21 (07) 947-956
    CrossrefPubMedGoogle Scholar
  • 66 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61 (06) 1968-1977
    CrossrefPubMedGoogle Scholar
  • 67 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
    CrossrefPubMedGoogle Scholar
  • 68 Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7 (11) 2587-2596
    CrossrefPubMedGoogle Scholar
  • 69 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 70 Tan DJH, Lim WH, Yong JN. et al. UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies. Clin Gastroenterol Hepatol 2023; 21 (06) 1475-1484
    CrossrefPubMedGoogle Scholar
  • 71 Ravaioli M, Grazi GL, Piscaglia F. et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8 (12) 2547-2557
    CrossrefPubMedGoogle Scholar
  • 72 Durkin C, Kaplan DE, Bittermann T. T2 hepatocellular carcinoma exception policies that prolong waiting time improve the use of evidence-based treatment practices. Transplant Direct 2020; 6 (09) e597
    CrossrefPubMedGoogle Scholar
  • 73 Kulik L, Heimbach JK, Zaiem F. et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology 2018; 67 (01) 381-400
    CrossrefPubMedGoogle Scholar
  • 74 Kubal C, Mihaylov P, Holden J. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. Curr Opin Organ Transplant 2021; 26 (02) 168-175
    CrossrefPubMedGoogle Scholar
  • 75 Organ Procurement and Transplantation Network (OPTN)OPTN. Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exceptions for Hepatocellular Carcinoma (HCC). Published online August 4, 2020. Accessed November 6, 2023 at: https://optn.transplant.hrsa.gov/media/gqlnhrtn/20200804_nlrb_adult_hcc_guidance.pdf
    PubMed
  • 76 Cotter TG, Minhem M, Wang J. et al. Living donor liver transplantation in the United States: evolution of frequency, outcomes, center volumes, and factors associated with outcomes. Liver Transpl 2021; 27 (07) 1019-1031
    CrossrefPubMedGoogle Scholar
  • 77 Kulik LM, Fisher RA, Rodrigo DR. et al; A2ALL Study Group. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant 2012; 12 (11) 2997-3007
    CrossrefPubMedGoogle Scholar
  • 78 Silverstein J, Yao FY, Grab JD. et al. National experience with living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2022; 28 (07) 1144-1157
    CrossrefPubMedGoogle Scholar
  • 79 Choi SB, Kim HJ, Song TJ, Ahn HS, Choi SY. Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatobiliary Pancreat Sci 2014; 21 (09) 639-647
    CrossrefPubMedGoogle Scholar
  • 80 Citterio D, Facciorusso A, Sposito C, Rota R, Bhoori S, Mazzaferro V. Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma. JAMA Surg 2016; 151 (09) 846-853
    CrossrefPubMedGoogle Scholar
  • 81 Rajakannu M, Cherqui D, Ciacio O. et al. Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma. Surgery 2017; 162 (04) 766-774
    CrossrefPubMedGoogle Scholar
  • 82 Maegawa FB, Shehorn L, Aziz H, Kettelle J, Jie T, Riall TS. Association between noninvasive fibrosis markers and postoperative mortality after hepatectomy for hepatocellular carcinoma. JAMA Netw Open 2019; 2 (01) e187142
    CrossrefPubMedGoogle Scholar
  • 83 Di Benedetto F, Magistri P, Di Sandro S. et al; Robotic HPB Study Group. Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma. JAMA Surg 2023; 158 (01) 46-54
    CrossrefPubMedGoogle Scholar
  • 84 Murtha-Lemekhova A, Fuchs J, Hoffmann K. Innovation for the sake of innovation? How does robotic hepatectomy compare to laparoscopic or open resection for HCC - a systematic review and meta-analysis. Cancers (Basel) 2022; 14 (14) 3359
    CrossrefPubMedGoogle Scholar
  • 85 Llovet JM, De Baere T, Kulik L. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021; 18 (05) 293-313
    CrossrefPubMedGoogle Scholar
  • 86 Lee DH, Lee JM, Lee JY. et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology 2014; 270 (03) 900-909
    CrossrefPubMedGoogle Scholar
  • 87 N'Kontchou G, Mahamoudi A, Aout M. et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50 (05) 1475-1483
    CrossrefPubMedGoogle Scholar
  • 88 Wicks JS, Dale BS, Ruffolo L. et al. Comparable and complimentary modalities for treatment of small-sized HCC: surgical resection, radiofrequency ablation, and microwave ablation. J Clin Med 2023; 12 (15) 5006
    CrossrefPubMedGoogle Scholar
  • 89 Poggi G, Tosoratti N, Montagna B, Picchi C. Microwave ablation of hepatocellular carcinoma. World J Hepatol 2015; 7 (25) 2578-2589
    CrossrefPubMedGoogle Scholar
  • 90 Yu J, Yu XL, Han ZY. et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 2017; 66 (06) 1172-1173
    CrossrefPubMedGoogle Scholar
  • 91 Vietti Violi N, Duran R, Guiu B. et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 2018; 3 (05) 317-325
    CrossrefPubMedGoogle Scholar
  • 92 Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104 (02) 514-524
    CrossrefPubMedGoogle Scholar
  • 93 Takayama T, Hasegawa K, Izumi N. et al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial). Liver Cancer 2021; 11 (03) 209-218
    CrossrefPubMedGoogle Scholar
  • 94 Kim BH. Surgical resection versus ablation for early hepatocellular carcinoma: the debate is still open. Clin Mol Hepatol 2022; 28 (02) 174-176
    CrossrefPubMedGoogle Scholar
  • 95 Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection versus local ablation therapies for hepatocellular carcinoma within the milan criteria: a systematic review and meta-analysis. Ann Surg 2021; 273 (04) 656-666
    CrossrefPubMedGoogle Scholar
  • 96 Garg T, Shrigiriwar A, Habibollahi P. et al. Intraarterial therapies for the management of hepatocellular carcinoma. Cancers (Basel) 2022; 14 (14) 3351
    CrossrefPubMedGoogle Scholar
  • 97 Lee EW, Khan S. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2017; 23 (04) 265-272
    CrossrefPubMedGoogle Scholar
  • 98 Brown AM, Kassab I, Massani M. et al. TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis. Cancer Med 2023; 12 (03) 2590-2599
    CrossrefPubMedGoogle Scholar
  • 99 Kudo M, Ueshima K, Ikeda M. et al; TACTICS Study Group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69 (08) 1492-1501
    CrossrefPubMedGoogle Scholar
  • 100 Kudo M, Ueshima K, Ikeda M. et al. Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. Liver Cancer 2022; 11 (04) 354-367
    CrossrefPubMedGoogle Scholar
  • 101 Yu Q, Khanjyan M, Fidelman N, Pillai A. Contemporary applications of Y90 for the treatment of hepatocellular carcinoma. Hepatol Commun 2023; 7 (10) e0288
    PubMedGoogle Scholar
  • 102 Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol 2021; 75 (04) 960-974
    CrossrefPubMedGoogle Scholar
  • 103 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021; 18 (08) 525-543
    CrossrefPubMedGoogle Scholar
  • 104 Weinmann A, Galle PR. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Curr Oncol 2020; 27 (Suppl. 03) S152-S164
    CrossrefPubMedGoogle Scholar
  • 105 Llovet JM, Ricci S, Mazzaferro V. et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
    CrossrefPubMedGoogle Scholar
  • 106 Yamashita T, Kudo M, Ikeda K. et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 2020; 55 (01) 113-122
    CrossrefPubMedGoogle Scholar
  • 107 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
    CrossrefPubMedGoogle Scholar
  • 108 Abou-Alfa GK, Lau G, Kudo M. et al. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer). Future Oncol 2023; DOI: 10.2217/fon-2023-0486.
    CrossrefPubMedGoogle Scholar
  • 109 Aby ES, Pillai A. HiCCups in management - pitfalls and pearls for the management of HCC. Clin Liver Dis (Hoboken) 2023; 22 (03) 85-88
    CrossrefPubMedGoogle Scholar